Clinical Scorecard: Successful Long-Term Management and Discontinuation of Low-Dose Sirolimus in an Adult Patient with Kaposiform Lymphangiomatosis and Disseminated Intravascular Coagulation: A Case Study

At a Glance

Key Highlights

• Long-term low-dose sirolimus (1 mg/day) led to significant clinical and laboratory improvements.
• Patient remained stable for five years post-sirolimus discontinuation.
• KLA is associated with high morbidity and mortality, often complicated by DIC.
• Diagnosis of KLA is challenging due to heterogeneous clinical presentation.
• Durable remission after sirolimus withdrawal is rarely reported in adult KLA cases.

Guideline-Based Recommendations

Diagnosis

• Diagnosis based on clinical, imaging, histopathological, and molecular findings.

Management

• Long-term low-dose sirolimus therapy is effective in controlling disease progression.

Monitoring & Follow-up

• Regular monitoring of sirolimus trough levels (4–5 ng/mL) and laboratory parameters.

Risks

• Potential for mild adverse effects such as oral ulcers and acne; no severe infections or organ toxicity reported.

Patient & Prescribing Data

Adult male with confirmed NRAS p.Q61R mutation and KLA complicated by DIC.

Sirolimus was well tolerated with only mild side effects; effective in achieving disease control.

Clinical Best Practices

• Individualized dosing and careful monitoring during sirolimus therapy.
• Consideration of treatment withdrawal after sustained remission.

Related Resources & Content

• Kaposiform lymphangiomatosis case study